APTITUDE HEALTH®

EPICS

Global Perspectives: Early-Stage Lung Cancer in 2023

December 15, 2023

Full Report

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
December 15, 2023



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lung cancer
- > 6 from US
- > 2 from Europe

EARLY LUNG CANCER-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 6 North American and 2 European Lung Cancer Experts

EPICS

Jonathan Spicer, MD, PhD
McGill University

Lynette Sholl, MD
Brigham and Women's Hospital

CHAIR:
Corey Langer, MD, FACP
University of Pennsylvania

Charles Simone II, MD, FASTRO, FACRO
Memorial Sloan Kettering Cancer Center

Nasser Hanna, MD
Indiana University Health

Andrew Haas, MD, PhD
Penn Medicine

Solange Peters, MD, PhD
Centre Hospitalier
Universitaire Vaudois

Enriqueta Felip, MD, PhD
Vall d'Hebron University

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time (ET)	Topic	Speaker/Moderator
1.30 PM – 1.35 PM	Welcome, Introductions, and Meeting Objectives	Corey Langer, MD, FACP
1.35 PM – 1.55 PM	Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative?	Solange Peters, MD, PhD; Charles Simone II, MD, FASTRO, FACRO
1.55 PM – 2.30 PM	Discussion	All
2.30 PM – 2.35 PM	Key Takeaways	Solange Peters, MD, PhD; Charles Simone II, MD, FASTRO, FACRO
2.35 PM – 2.50 PM	Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy?	Enriqueta Felip, MD, PhD
2.50 PM – 3.10 PM	Discussion	All
3.10 PM – 3.15 PM	Key Takeaways	Enriqueta Felip, MD, PhD
3.15 PM – 3.25 PM	The Road Forward for Other Drivers and Targets in Resectable NSCLC	Nasser Hanna, MD
3.25 PM – 3.45 PM	Discussion	All
3.45 PM – 3.50 PM	Key Takeaways	Nasser Hanna, MD
3.50 PM – 4.05 PM	Predictive Markers: Who Needs More Therapy, Who Needs Less?	Lynette Sholl, MD
4.05 PM – 4.20 PM	Discussion	All
4.20 PM – 4.25 PM	Key Takeaways	Lynette Sholl, MD
4.25 PM – 4.30 PM	Summary and Closing Remarks	Corey Langer, MD, FACP

APTITUDE HEALTH®

EPICS

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative?

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (1/2)

Presented by Solange Peters, MD, PhD, and Charles Simone II, MD, FASTRO, FACRO

EPICS

STUDY POPULATION

- [illegible]

OUTCOMES

- [illegible]

EXPERT CONCLUSIONS

[illegible]

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (2/2)

Presented by Solange Peters, MD, PhD, and Charles Simone II, MD, FASTRO, FACRO

EPICS

Immunotherapy in Resectable NSCLC (cont.)

APTITUDE HEALTH®

EPICS

Key Insights

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative?

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (1/4)

EPICS

> In general, the experts use neoadjuvant chemotherapy plus immunotherapy in patients with resectable stage IIA–IIIA NSCLC

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (2/4)

EPICS

> The pathology expert commented on assessment of PD-L1 and pathologic response

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (3/4)

EPICS

> The experts agreed more data are needed to determine the best management approach following surgery

Immunotherapy: Neoadjuvant, Adjuvant, or Perioperative? (4/4)

EPICS

> For patients with medically inoperable, early-stage NSCLC, the opinion of the RT expert is that the standard of care will be to use

APTITUDE HEALTH®

EPICS

Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy?

Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy? (1/2)

Presented by Enriqueta Felip, MD, PhD

EPICS

- Therapeutic options are increasing for

Adjuvant Treatment With Targeted Agents

Timeline of FDA Approvals for HER2+ Breast Cancer

Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy? (2/2)

Presented by Enriqueta Felip, MD, PhD

EPICS

> Treatment guidelines recommend adjuvant chemotherapy in patients with resected disease, and do not exclude patients with oncogenic

APTITUDE HEALTH®

EPICS

Key Insights

Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy?

Oncogene-Driven NSCLC: *EGFR/ALK* – Do These Approaches Complement or Replace Chemotherapy?

EPICS

> For patients with resectable, *ALK*-rearranged NSCLC, the experts agreed all patients should receive adjuvant chemotherapy, even though the

patients with non-squamous histology

APTITUDE HEALTH®

EPICS

The Road Forward for Other Drivers and Targets in Resectable NSCLC

The Road Forward for Other Drivers and Targets in Resectable NSCLC (1/2)

Presented by Nasser Hanna, MD

EPICS

The Road Forward for Other Drivers and Targets in Resectable NSCLC (2/2)

Presented by Nasser Hanna, MD

EPICS

> Several trials are ongoing to evaluate targeted therapy in patients with oncogene-driven, resectable NSCLC

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Key Insights

The Road Forward for Other Drivers and Targets in Resectable NSCLC

The Road Forward for Other Drivers and Targets in Resectable NSCLC (1/2)

EPICS

> The pathology expert stated that testing for an expanding array of biomarkers in early-stage NSCLC will bring several challenges

The Road Forward for Other Drivers and Targets in Resectable NSCLC (2/2)

EPICS

> Regarding the prospects for ADCs in early-stage NSCLC, expert opinion is that these agents have demonstrated more toxicity than expected:

APTITUDE HEALTH®

EPICS

Predictive Markers: Who Needs More Therapy, Who Needs Less?

Predictive Markers: Who Needs More Therapy, Who Needs Less? (1/2)

Presented by Lynette Sholl, MD

EPICS

- While regimens of neoadjuvant and

Potential for personalized ctDNA assay to identify

Timeline of FDA Approvals for HER2+ Breast Cancer

Predictive Markers: Who Needs More Therapy, Who Needs Less? (2/2)

Presented by Lynette Sholl, MD

EPICS

- In patients with *KRAS* mutations, co-mutations in genes such as *STK11* have been correlated with reduced benefit from immunotherapy;

APTITUDE HEALTH®

EPICS

Key Insights

Predictive Markers: Who Needs More Therapy, Who Needs Less?

Predictive Markers: Who Needs More Therapy, Who Needs Less?

EPICS

- There was enthusiasm from the experts regarding the data from the TRACERx study (ESMO 2023, abstract LBA55) that demonstrated

APTITUDE HEALTH®

US 5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com